InflaRx (IFRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a treatment targeting SARS-CoV-2-induced acute respiratory distress syndrome in adults. This recommendation, pending European Commission approval, highlights the drug’s potential to improve survival rates in critically ill COVID-19 patients. The development marks a significant milestone for InflaRx, boosting its stock appeal amidst ongoing challenges in COVID-19 treatment.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.